51
|
Evaluation of Histological, Immunohistochemical, Clinical and Genetic Prognostic Factors Associated with the Response of Canine Mast Cell Tumours to Glucocorticotherapy. J Comp Pathol 2018; 165:72-81. [PMID: 30502801 DOI: 10.1016/j.jcpa.2018.10.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2018] [Revised: 08/29/2018] [Accepted: 10/11/2018] [Indexed: 11/20/2022]
Abstract
Mast cell tumours (MCTs) are one of the most frequent neoplasms in dogs. Glucocorticoids (GCs) are widely used in the management of this disease, although no guidelines for their use have been established. The aim of this study was to evaluate the correlation of MCT prognostic factors with measurable response to GCs. This retrospective study included 60 dogs treated with prednisone or prednisolone prior to surgical biopsy of MCT. Incisional or excisional biopsy was performed 7-14 days after initiation of GC therapy. Histopathology, immunohistochemical labelling for Ki67 and KITr, and polymerase chain reaction for the c-KIT gene were performed. Partial response occurred in 63.3% of cases (38/60), while 36.7% (22/60) did not respond. A response to GCs was correlated with lower stage of the disease, low histological grade, lower pattern of KITr expression and Ki67 score. Response to GCs was positively correlated with well-established favourable prognostic factors.
Collapse
|
52
|
Sulce M, Marconato L, Martano M, Iussich S, Dentini A, Melega M, Miniscalco B, Riondato F. Utility of flow cytometry in canine primary cutaneous and matched nodal mast cell tumor. Vet J 2018; 242:15-23. [DOI: 10.1016/j.tvjl.2018.10.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2017] [Revised: 08/31/2018] [Accepted: 10/09/2018] [Indexed: 02/01/2023]
|
53
|
Machado GA, Fontes TN, Larangeira DF, Estrela-Lima A, Moreira EL, Ribeiro LS, Pinto MP, Peixoto TC. Incidence of skin tumors in dogs in Salvador, Bahia state, Brazil (2007-2016). PESQUISA VETERINÁRIA BRASILEIRA 2018. [DOI: 10.1590/1678-5150-pvb-5686] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
ABSTRACT: This study aimed to establish the incidence of skin tumors (cutaneous proliferative lesions of neoplastic or non-neoplastic nature) in dogs diagnosed by histopathological evaluation at the Veterinary Pathology Laboratory (LPV) of the Federal University of Bahia (UFBA) in a 10-year (2007-2016) historical series. Of the 1945 histopathological diagnoses made in this period, 503 were skin biopsies, and 617 dermatological problems (87 dogs, 17.3%, presented more than one positive diagnosis) were found. Of the 617 diagnoses of dermatopathy, 546 (88.49%) were tumors and 71 (11.51%) were non-tumorous alterations. The 546 conditions more profoundly studied were from 453 dogs, 468 (85.7%) neoplastic and 78 (14.3%) non-neoplastic tumors. The 468 neoplasms were classified as follows: 230 benign (49.14%), 215 malignant (45.94%), 23 borderline (epitheliomas) (4.91%), 51.92% (243/468) mesenchymal, 42.74% (200/468) epithelial, 4.91% (23/468) melanocytic, and 0.43% (2/468) metastatic (mammary gland). The most commonly diagnosed neoplastic dermatopathies were mastocytoma (14.7%) and lipoma (7.48%). Among the 78 non-neoplastic conditions (14.3%), epidermal inclusion cyst (39.74%) and trichogranuloma (15.38%) were the most frequent. Canine dermatopathies accounted for 26% of the biopsy files of the LPV-UFBA. Distinct simultaneous dermatological problems were frequently found in the dogs assessed (one in six). Considering that these conditions can present with different cellular origin and biological behavior, it is crucial that histopathological evaluation be performed in fragments from the different cutaneous lesions.
Collapse
|
54
|
Willmann M, Hadzijusufovic E, Hermine O, Dacasto M, Marconato L, Bauer K, Peter B, Gamperl S, Eisenwort G, Jensen-Jarolim E, Müller M, Arock M, Vail DM, Valent P. Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms. Vet Comp Oncol 2018; 17:1-10. [PMID: 30136349 PMCID: PMC6378619 DOI: 10.1111/vco.12440] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2018] [Revised: 08/14/2018] [Accepted: 08/16/2018] [Indexed: 12/13/2022]
Abstract
In humans, advanced mast cell (MC) neoplasms are rare malignancies with a poor prognosis. Only a few preclinical models are available, and current treatment options are limited. In dogs, MC neoplasms are the most frequent malignant skin tumours. Unlike low‐grade MC neoplasms, high‐grade MC disorders usually have a poor prognosis with short survival. In both species, neoplastic MCs display activating KIT mutations, which are considered to contribute to disease evolution. Therefore, tyrosine kinase inhibitors against KIT have been developed. Unfortunately, clinical responses are unpredictable and often transient, which remains a clinical challenge in both species. Therefore, current efforts focus on the development of new improved treatment strategies. The field of comparative oncology may assist in these efforts and accelerate human and canine research regarding diagnosis, prognostication, and novel therapies. In this article, we review the current status of comparative oncology approaches and perspectives in the field of MC neoplasms.
Collapse
Affiliation(s)
- Michael Willmann
- Department of Companion Animals and Horses, Clinic for Internal Medicine, University of Veterinary Medicine Vienna, Vienna, Austria.,Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria
| | - Emir Hadzijusufovic
- Department of Companion Animals and Horses, Clinic for Internal Medicine, University of Veterinary Medicine Vienna, Vienna, Austria.,Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria.,Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
| | - Olivier Hermine
- Department of Hematology, Necker Hospital, Imagine Institute Université Paris Descartes, Sorbonne, Paris, France
| | - Mauro Dacasto
- Department of Comparative Biomedicine and Food Science, University of Padua, Padua, Italy
| | | | - Karin Bauer
- Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria.,Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
| | - Barbara Peter
- Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria.,Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
| | - Susanne Gamperl
- Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
| | - Gregor Eisenwort
- Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria.,Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
| | - Erika Jensen-Jarolim
- Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.,The Interuniversity Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University Vienna, University of Vienna, Vienna, Austria
| | - Mathias Müller
- Biomodels Austria and Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, Austria
| | - Michel Arock
- LBPA CNRS UMR8113, Ecole Normale Supérieure de Cachan, Cachan, France.,Laboratory of Hematology, Pitié-Salpêtrière Hospital, Paris, France
| | - David M Vail
- Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin.,Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin
| | - Peter Valent
- Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria.,Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
| |
Collapse
|
55
|
Marconato L, Polton G, Stefanello D, Morello E, Ferrari R, Henriques J, Tortorella G, Benali SL, Bergottini R, Vasconi ME, Annoni M, Sabattini S. Therapeutic impact of regional lymphadenectomy in canine stage II cutaneous mast cell tumours. Vet Comp Oncol 2018; 16:580-589. [DOI: 10.1111/vco.12425] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2018] [Revised: 05/30/2018] [Accepted: 06/18/2018] [Indexed: 01/20/2023]
Affiliation(s)
| | | | - Damiano Stefanello
- Dipartimento di Medicina Veterinaria; Università degli Studi di Milano; Milan Italy
| | - Emanuela Morello
- Department of Veterinary Sciences; University of Torino; Turin Italy
| | - Roberta Ferrari
- Dipartimento di Medicina Veterinaria; Università degli Studi di Milano; Milan Italy
| | | | | | | | | | | | | | - Silvia Sabattini
- Department of Veterinary Medical Sciences; University of Bologna; Bologna Italy
| |
Collapse
|
56
|
Joselevitch JA, Barra CN, Vargas THM, Pulz LH, Nishiya AT, Kleeb SR, Xavier JG, Catão-Dias JL, Strefezzi RF. Nanog Expression and Proliferation Indices in Canine Cutaneous Mast Cell Tumors. Vet Pathol 2018; 55:849-852. [PMID: 30025495 DOI: 10.1177/0300985818789470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Mast cell tumors are one of the most frequent skin tumors in dogs. Treatment decisions often depend on a wide range of clinical information and the main criteria for prognostic formulation are histological grade, mitotic count, Ki67 index, and KIT immunostaining pattern. NANOG is a pluripotency factor expressed by normal and cancer stem cells, which is a prognostic marker and a potential therapeutic target for several human tumors. In the present study, mast cell tumor samples from 41 dogs were evaluated for NANOG and Ki67 by immunohistochemistry. All samples were positive for NANOG but its expression was not correlated with Ki67 index and no significant differences were found with respect to histopathological grades, disease-related mortality, or survival. Our results suggest that, although related to pluripotency, NANOG expression does not correlate with proliferative activity, and is not a reliable prognostic factor for canine cutaneous mast cell tumors.
Collapse
Affiliation(s)
- Julia A Joselevitch
- 1 Laboratório de Oncologia Comparada e Translacional (LOCT), Departamento de Medicina Veterinária, Faculdade de Zootecnia e Engenharia de Alimentos, Universidade de São Paulo, Pirassununga, São Paulo, Brazil
| | - Camila N Barra
- 1 Laboratório de Oncologia Comparada e Translacional (LOCT), Departamento de Medicina Veterinária, Faculdade de Zootecnia e Engenharia de Alimentos, Universidade de São Paulo, Pirassununga, São Paulo, Brazil.,2 Departamento de Patologia, Faculdade de Medicina Veterinária e Zootecnia, Universidade de São Paulo, São Paulo, Brazil
| | - Thiago Henrique M Vargas
- 1 Laboratório de Oncologia Comparada e Translacional (LOCT), Departamento de Medicina Veterinária, Faculdade de Zootecnia e Engenharia de Alimentos, Universidade de São Paulo, Pirassununga, São Paulo, Brazil
| | - Lidia H Pulz
- 1 Laboratório de Oncologia Comparada e Translacional (LOCT), Departamento de Medicina Veterinária, Faculdade de Zootecnia e Engenharia de Alimentos, Universidade de São Paulo, Pirassununga, São Paulo, Brazil.,2 Departamento de Patologia, Faculdade de Medicina Veterinária e Zootecnia, Universidade de São Paulo, São Paulo, Brazil
| | | | - Silvia Regina Kleeb
- 4 Universidade Metodista de São Paulo, São Bernardo do Campo, São Paulo, Brazil
| | | | - José Luiz Catão-Dias
- 2 Departamento de Patologia, Faculdade de Medicina Veterinária e Zootecnia, Universidade de São Paulo, São Paulo, Brazil
| | - Ricardo F Strefezzi
- 1 Laboratório de Oncologia Comparada e Translacional (LOCT), Departamento de Medicina Veterinária, Faculdade de Zootecnia e Engenharia de Alimentos, Universidade de São Paulo, Pirassununga, São Paulo, Brazil
| |
Collapse
|
57
|
Berlato D, Murphy S, Laberke S, Rasotto R. Comparison of minichromosome maintenance protein 7, Ki67 and mitotic index in the prognosis of intermediate Patnaik grade cutaneous mast cell tumours in dogs. Vet Comp Oncol 2018; 16:535-543. [DOI: 10.1111/vco.12412] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2018] [Revised: 05/04/2018] [Accepted: 05/08/2018] [Indexed: 12/26/2022]
Affiliation(s)
- D. Berlato
- Centre for Small Animal Studies; Animal Health Trust; Newmarket UK
| | - S. Murphy
- Centre for Small Animal Studies; Animal Health Trust; Newmarket UK
| | - S. Laberke
- Centre for Small Animal Studies; Animal Health Trust; Newmarket UK
| | - R. Rasotto
- Centre for Small Animal Studies; Animal Health Trust; Newmarket UK
| |
Collapse
|
58
|
Ilyinskaya GV, Mukhina EV, Soboleva AV, Matveeva OV, Chumakov PM. Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study). Front Vet Sci 2018; 5:116. [PMID: 29915788 PMCID: PMC5995045 DOI: 10.3389/fvets.2018.00116] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2017] [Accepted: 05/15/2018] [Indexed: 12/21/2022] Open
Abstract
Background: Canine mastocytomas (mast cell tumors) represent a common malignancy among many dog breeds. A typical treatment strategy for canine mastocytomas includes surgery, chemo- and radio-therapy, although in many cases the therapy fails and the disease progression resumes. New treatment approaches are needed. Aims: The goal of this pilot study was to examine safety and efficacy of oncolytic Sendai virus therapy administered to canine patients with cutaneous or subcutaneous mastocytomas. Materials and Methods: Six canine patients, with variable grades and stages of the disease, received virus therapy, either as a monotherapy, or in combination with surgery. The therapy included two or more virus applications administered weekly or biweekly. Each application of Sendai virus (107-108.6 EID50) consisted of multiple individual 0.01-0.1 ml injections delivered intratumorally, intradermally around a tumor, and under a tumor bed. Results: The treatment was well tolerated, with minor transitory side effects. Of the six dogs, two did not receive surgery or any other treatment besides the virus injections. The other four animals underwent radical or debulking surgeries, and in three of them the subsequent administration of Sendai virus completely cleared locally recurrent or/and remaining tumor masses. Five dogs demonstrated a complete response to the treatment, the animals remained disease free during the time of observation (2-3 years). One dog responded only partially to the virotherapy; its after-surgical recurrent tumor and some, but not all, metastases were cleared. This dog had the most advanced stage of the disease with multiple enlarged lymph nodes and cutaneous metastases. Conclusion: The results of the pilot study suggest that Sendai virus injections could be safe and efficient for the treatment of dogs affected by mastocytomas.They also suggest the need of further studies for finding optimal schemes and schedules for this kind of therapy.
Collapse
Affiliation(s)
- Galina V. Ilyinskaya
- Engelhardt Institute of Molecular Biology, Moscow, Russia
- Blokhin Cancer Research Center, Moscow, Russia
| | - Elena V. Mukhina
- Veterinary Clinic of Herzen Oncology Research Institute, Moscow, Russia
| | - Alesya V. Soboleva
- Engelhardt Institute of Molecular Biology, Moscow, Russia
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products, Moscow, Russia
| | | | - Peter M. Chumakov
- Engelhardt Institute of Molecular Biology, Moscow, Russia
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products, Moscow, Russia
| |
Collapse
|
59
|
Musser M, Berger E, Flaherty HA, Fox L, Johannes CM. Marked paraneoplastic hypereosinophilia associated with a low‐grade, metastatic canine mast cell tumour. VETERINARY RECORD CASE REPORTS 2018. [DOI: 10.1136/vetreccr-2017-000563] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Margaret Musser
- College of Veterinary MedicineIowa State UniversityAmesIowaUSA
| | - Erika Berger
- College of Veterinary MedicineIowa State UniversityAmesIowaUSA
| | | | - Leslie Fox
- College of Veterinary MedicineIowa State UniversityAmesIowaUSA
| | - Chad M Johannes
- College of Veterinary MedicineIowa State UniversityAmesIowaUSA
| |
Collapse
|
60
|
Blackwood L, Tanis JB, Harper A, Amores-Fuster I, Killick DR, Finotello R. Acute radiotherapy toxicity in 57 dogs with gross and microscopic mast cell tumours. Vet Comp Oncol 2018; 16:431-440. [PMID: 29761612 DOI: 10.1111/vco.12398] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2017] [Revised: 03/08/2018] [Accepted: 03/14/2018] [Indexed: 10/16/2022]
Abstract
Mast cell tumours (MCTs) are commonly treated with radiation therapy, most often in a microscopic disease setting. Poorer outcomes are expected in patients with gross disease, and irradiation of gross disease may be associated with greater toxicity. The aim of this study was to compare acute radiation adverse events (AE) in dogs with gross and microscopic MCTs receiving radiotherapy. Fifty-seven dogs were included, 28 with gross disease and 29 with microscopic. In order to assess mucosal and skin toxicity, patients were assigned to 2 groups: head (29 patients, 14 patients with gross and 15 microscopic) and other sites (28 patients, 14 each). All were treated with external beam radiotherapy, and toxicity assessed at the end of treatment and 10 to 14 days later (first recheck). All patients developed some acute radiation toxicity by the end of the course. However, there was no difference in the severity of toxicity between gross and microscopic disease in either site group at either time point. The only variable associated with an increased frequency of grade 2 or 3 toxicity at the first recheck was the use of prednisolone prior to radiotherapy (P = .05). No other factors were identified which were associated with increased toxicity. For the head group, the site of highest grade toxicity was mucosa or, if included in the field, nasal planum, which was often more severely affected than the mucosa. No significant late toxicity was identified. Two dogs developed acute haematemesis during the radiotherapy course, but both completed the course without further events.
Collapse
Affiliation(s)
- L Blackwood
- Department of Small Animal Clinical Science, University of Liverpool, Leahurst Campus, Neston, Cheshire, UK
| | - J B Tanis
- Department of Small Animal Clinical Science, University of Liverpool, Leahurst Campus, Neston, Cheshire, UK
| | - A Harper
- Department of Small Animal Clinical Science, University of Liverpool, Leahurst Campus, Neston, Cheshire, UK
| | - I Amores-Fuster
- Department of Small Animal Clinical Science, University of Liverpool, Leahurst Campus, Neston, Cheshire, UK
| | - D R Killick
- Department of Small Animal Clinical Science, University of Liverpool, Leahurst Campus, Neston, Cheshire, UK
| | - R Finotello
- Department of Small Animal Clinical Science, University of Liverpool, Leahurst Campus, Neston, Cheshire, UK
| |
Collapse
|
61
|
Horta RDS, Giuliano A, Lavalle GE, Costa MDP, de Araújo RB, Constantino-Casas F, Dobson JM. Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors. Oncol Lett 2018; 15:129-136. [PMID: 29387214 PMCID: PMC5768098 DOI: 10.3892/ol.2017.7323] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2017] [Accepted: 09/01/2017] [Indexed: 11/29/2022] Open
Abstract
The aim of the present prospective-retrospective study was to evaluate the response of high-risk canine mast cell tumours (MCTs) to tyrosine kinase inhibitors (TKIs) and to correlate this with prognostic factors. A total of 24 dogs presented with macroscopic cutaneous MCTs at disease stage II or III, and therefore, at high-risk of associated mortality, were included in the study and treated with masitinib (n=20) or toceranib (n=4). A total of 12/24 dogs achieved an objective response and the overall survival (OS) for all subjects was 113 days. Dogs responding to treatment had a significant increase in OS compared to non-responders (146.5 days vs. 47 days, P=0.02). Internal tandem duplications in exon 11 of the c-kit gene were identified in 6/24 cases. Ki67, KIT immunolabelling and c-kit mutation did not provide information regarding prognosis or prediction of response to TKIs in this population. Initial response to TKIs appears to be the most reliable prognostic factor for survival duration.
Collapse
Affiliation(s)
- Rodrigo Dos Santos Horta
- Department of Veterinary Medicine, Universidade Vila Velha (UVV), Vila Velha, ES 29120-920, Brazil
| | - Antonio Giuliano
- Department of Veterinary Medicine, The Queen's Veterinary School Hospital, University of Cambridge, Cambridge CB3 0ES, UK
| | - Gleidice Eunice Lavalle
- Department of Veterinary Clinic and Surgery, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG 31270-901, Brazil
| | - Mariana de Pádua Costa
- Department of Veterinary Clinic and Surgery, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG 31270-901, Brazil
| | - Roberto Baracat de Araújo
- Department of Veterinary Clinic and Surgery, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG 31270-901, Brazil
| | - Fernando Constantino-Casas
- Department of Veterinary Medicine, The Queen's Veterinary School Hospital, University of Cambridge, Cambridge CB3 0ES, UK
| | - Jane Margaret Dobson
- Department of Veterinary Medicine, The Queen's Veterinary School Hospital, University of Cambridge, Cambridge CB3 0ES, UK
| |
Collapse
|
62
|
Horta RS, Lavalle GE, Monteiro LN, Souza MCC, Cassali GD, Araújo RB. Assessment of Canine Mast Cell Tumor Mortality Risk Based on Clinical, Histologic, Immunohistochemical, and Molecular Features. Vet Pathol 2018; 55:212-223. [DOI: 10.1177/0300985817747325] [Citation(s) in RCA: 49] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Mast cell tumor (MCT) is a frequent cutaneous neoplasm in dogs that is heterogeneous in clinical presentation and biological behavior, with a variable potential for recurrence and metastasis. Accurate prediction of clinical outcomes has been challenging. The study objective was to develop a system for classification of canine MCT according to the mortality risk based on individual assessment of clinical, histologic, immunohistochemical, and molecular features. The study included 149 dogs with a histologic diagnosis of cutaneous or subcutaneous MCT. By univariate analysis, MCT metastasis and related death was significantly associated with clinical stage ( P < .0001, rP = –0.610), history of tumor recurrence ( P < .0001, rP = –0.550), Patnaik ( P < .0001, rP = –0.380) and Kiupel grades ( P < .0001, rP = –0.500), predominant organization of neoplastic cells ( P < .0001, rP = –0.452), mitotic count ( P < .0001, rP = –0.325), Ki-67 labeling index ( P < .0001, rP = –0.414), KITr pattern ( P = .02, rP = 0.207), and c-KIT mutational status ( P < .0001, rP = –0.356). By multivariate analysis with Cox proportional hazard model, only 2 features were independent predictors of overall survival: an amendment of the World Health Organization clinical staging system (hazard ratio [95% CI]: 1.824 [1.210-4.481]; P = .01) and a history of tumor recurrence (hazard ratio [95% CI]: 9.250 [2.158-23.268]; P < .001]. From these results, we propose an amendment of the WHO staging system, a method of risk analysis, and a suggested approach to clinical and laboratory evaluation of dogs with cutaneous MCT.
Collapse
Affiliation(s)
| | - Gleidice E. Lavalle
- Department of Veterinary Clinics and Surgery, Veterinary School, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | - Lidianne N. Monteiro
- Laboratory of Comparative Pathology, Biological Science Institute, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil
| | | | - Geovanni D. Cassali
- Laboratory of Comparative Pathology, Biological Science Institute, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil
| | - Roberto B. Araújo
- Department of Veterinary Clinics and Surgery, Veterinary School, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| |
Collapse
|
63
|
Flores AR, Azinhaga A, Pais E, Faria F, Nunes F, Gartner F, Amorim I. Equine ocular mast cell tumor: histopathological and immunohistochemical description. J Equine Sci 2017; 28:149-152. [PMID: 29270072 PMCID: PMC5735312 DOI: 10.1294/jes.28.149] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2017] [Accepted: 08/18/2017] [Indexed: 12/15/2022] Open
Abstract
This report describes an ocular mast cell tumor in a 13-year-old female sport horse. Clinical examination revealed a solitary firm mass located in the ocular mucosa, protruding from behind the left lower eyelid. The lesion was surgically removed and submitted to histopathology. Microscopically, the mass was composed of sheets of well-differentiated neoplastic round cells circumscribed by delicate connective tissue. Positive Giemsa and Toluidine Blue staining confirmed the presence of cytoplasmic granules. Neoplastic cells showed strong membranous and mild diffuse cytoplasmic immunoreactivity for c-KIT and a low KI-67 proliferative index. Based on these findings, a diagnosis of ocular mast cell tumor was made. Six months after surgical removal, no evidence of ocular lesion recurrence was detected.
Collapse
Affiliation(s)
- Ana R Flores
- Department of Pathology and Molecular Immunology of the Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal
| | - Ana Azinhaga
- Vetplus Veterinary Clinic Lda, 3200-532 Tomar, Portugal
| | | | - Fátima Faria
- Department of Pathology and Molecular Immunology of the Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal
| | - Francisco Nunes
- Vasco da Gama University School (EUVG), 3020-210 Coimbra, Portugal
| | - Fátima Gartner
- Department of Pathology and Molecular Immunology of the Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal.,Institute for Research and Innovation in Health (i3S), University of Porto, 4200-135 Porto, Portugal.,Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), 4200-465 Porto, Portugal
| | - Irina Amorim
- Department of Pathology and Molecular Immunology of the Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal.,Institute for Research and Innovation in Health (i3S), University of Porto, 4200-135 Porto, Portugal.,Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), 4200-465 Porto, Portugal
| |
Collapse
|
64
|
Weishaar KM, Ehrhart EJ, Avery AC, Charles JB, Elmslie RE, Vail DM, London CA, Clifford CA, Eickhoff JC, Thamm DH. c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine. J Vet Intern Med 2017; 32:394-405. [PMID: 29194765 PMCID: PMC5787208 DOI: 10.1111/jvim.14889] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2017] [Revised: 09/14/2017] [Accepted: 10/24/2017] [Indexed: 01/19/2023] Open
Abstract
Background KIT inhibitors, such as toceranib (TOC), and vinblastine (VBL) have not been prospectively compared in the treatment of macroscopic mast cell tumors (MCTs). Also, it is unknown whether VBL or TOC is superior for treating MCT without c‐kit mutations. Hypothesis/Objectives To determine the value of KIT genotyping and localization in treatment decisions for dogs with macroscopic MCT. We hypothesized that c‐kit mutated MCT would have a better response to TOC than VBL. Animals Eighty‐eight client‐owned dogs with macroscopic MCT. Methods Prospective, randomized trial. Dogs were randomized to TOC (2.75 mg/kg EOD) or VBL (2.5 mg/m2 weekly × 4 then EOW) by KIT localization and c‐kit mutation status using an adaptive randomization scheme. Results Sixty dogs were allocated to TOC and 28 to VBL. Of the dogs receiving TOC, 20% had c‐kit mutations, compared to 30% receiving VBL (P = 0.74). Overall response rates were 46% (TOC) and 30% (VBL) (odds ratio = 1.56 [0.62–3.92]; P = 0.28). Median progression‐free survival (PFS) for dogs receiving VBL was 78 days (7–1,521) and for TOC 95.5 (14–990); hazard ratio (HR) = 1.34 [0.72–2.50]; P = 0.36. Median overall survival (OS) was 241.5 days (10–1,521) for the VBL group and 159 (20–990) for the TOC group; HR = 0.80 ([0.45–1.41]; P = 0.44). Conclusions and Clinical Importance Neither PFS nor OS was significantly different between treatment groups. As the proportion of dogs with c‐kit mutations was not different between treatment groups in this population of dogs, c‐kit mutation status did not predict treatment response.
Collapse
Affiliation(s)
- K M Weishaar
- Department of Clinical Sciences, Flint Animal Cancer Center, Colorado State University, Fort Collins, CO
| | - E J Ehrhart
- Department of Microbiology, Immunology, and Pathology, Flint Animal Cancer Center, Colorado State University, Fort Collins, CO
| | - A C Avery
- Department of Microbiology, Immunology, and Pathology, Flint Animal Cancer Center, Colorado State University, Fort Collins, CO
| | - J B Charles
- Department of Clinical Sciences, Flint Animal Cancer Center, Colorado State University, Fort Collins, CO
| | - R E Elmslie
- VRCC Veterinary Specialty and Emergency Hospital, Englewood, CO
| | - D M Vail
- School of Veterinary Medicine and the Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI
| | - C A London
- The Ohio State University Veterinary Medical Center, Columbus, OH
| | | | - J C Eickhoff
- School of Veterinary Medicine and the Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI
| | - D H Thamm
- Department of Clinical Sciences, Flint Animal Cancer Center, Colorado State University, Fort Collins, CO
| |
Collapse
|
65
|
Horta R, Lavalle G, Costa M, Moura L, Marcinowska A, Araújo R. Outcome of adjuvant chemotherapy with lomustine, vinblastine and chlorambucil on management of canine mast cell tumour of high to intermediate risk. ARQ BRAS MED VET ZOO 2017. [DOI: 10.1590/1678-4162-9172] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
ABSTRACT In spite of the many available protocols, the use of chemotherapy for the management of canine mast cell tumours (MCT) remains empirical, and there is lack of criteria for the choice of protocol and definition of patients who may benefit from treatment. The objective of this study was to evaluate the outcome of dogs with MCT after adjuvant chemotherapy according to the risk of recurrence or metastasis proposed on the literature. This prospective study included 89 followed up dogs with prognosis assesment including clinical, histological, immunohistochemical and genetic features of canine MCT. Patients were grouped according to risk of recurrence and metastasis and recommended treatment with lomustine followed by chlorambucil if considered at high-risk, or vinblastine followed by chlorambucil if a patient was at intermediate risk. Outcome was defined by disease-free interval (DFI) and overall survival (OS) estimated by Kaplan-Meier curve. Adjuvant lomustine was useful for control of canine MCT of high-risk of recurrence or metastasis, but only when sequentially associated to chlorambucil with a DFI of 686 days and not reached OS. There was no difference in outcome in the intermediate-risk group despite choosen treatment. Patients at intermediate-to-low risk may not require adjuvant treatments, even in the absence of free surgical margins.
Collapse
Affiliation(s)
| | | | - M.P. Costa
- Universidade Federal de Minas Gerais, Brazil
| | - L.L. Moura
- Universidade Federal de Minas Gerais, Brazil
| | | | - R.B. Araújo
- Universidade Federal de Minas Gerais, Brazil
| |
Collapse
|
66
|
Krick EL, Kiupel M, Durham AC, Thaiwong T, Brown DC, Sorenmo KU. Investigating Associations Between Proliferation Indices, C-kit, and Lymph Node Stage in Canine Mast Cell Tumors. J Am Anim Hosp Assoc 2017; 53:258-264. [DOI: 10.5326/jaaha-ms-6265] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
ABSTRACT
Previous studies have evaluated cellular proliferation indices, KIT expression, and c-kit mutations to predict the clinical behavior of canine mast cell tumors (MCTs). The study purpose was to retrospectively compare mitotic index, argyrophilic nucleolar organizer regions (AgNORs)/nucleus, Ki-67 index, KIT labeling pattern, and internal tandem duplication mutations in c-KIT between stage I and stage II grade II MCTs. Medical records and tumor biopsy samples from dogs with Grade II MCTs with cytological or histopathological regional lymph node evaluation were included. Signalment, tumor location and stage, and presence of a recurrent versus de novo tumor were recorded. Mitotic index, AgNORs/nucleus, Ki-67, KIT staining pattern, and internal tandem duplication mutations in exon 11 of c-KIT were evaluated. Sixty-six tumors (51 stage I; 15 stage II) were included. Only AgNORs/nucleus and recurrent tumors were significantly associated with stage (odds ratio 2.8, 95% confidence interval [CI] 1.0–8.0, P = .049; odds ratio 8.8, 95% CI 1.1–69.5; P = .039). Receiver-operator characteristic analysis showed that the sensitivity and specificity of AgNORs/cell ≥ 1.87 were 93.3% and 27.4%, respectively, (area under the curve: 0.65) for predicting stage. Recurrent tumors and higher AgNORs/nucleus are associated with stage II grade II MCTs; however, an AgNOR cutoff value that reliably predicts lymph node metastasis was not determined.
Collapse
Affiliation(s)
- Erika Lauren Krick
- From the School of Veterinary Medicine (E.L.K.), Department of Pathobiology (A.C.D.), and Department of Clinical Studies (D.C.B., K.U.S.), Veterinary Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, Pennsylvania; and Department of Pathobiology and Diagnostic Investigations, Diagnostic Center for Population and Animal Health (M.K.), and the Comparative Medicine
| | - Matti Kiupel
- From the School of Veterinary Medicine (E.L.K.), Department of Pathobiology (A.C.D.), and Department of Clinical Studies (D.C.B., K.U.S.), Veterinary Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, Pennsylvania; and Department of Pathobiology and Diagnostic Investigations, Diagnostic Center for Population and Animal Health (M.K.), and the Comparative Medicine
| | - Amy C. Durham
- From the School of Veterinary Medicine (E.L.K.), Department of Pathobiology (A.C.D.), and Department of Clinical Studies (D.C.B., K.U.S.), Veterinary Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, Pennsylvania; and Department of Pathobiology and Diagnostic Investigations, Diagnostic Center for Population and Animal Health (M.K.), and the Comparative Medicine
| | - Tuddow Thaiwong
- From the School of Veterinary Medicine (E.L.K.), Department of Pathobiology (A.C.D.), and Department of Clinical Studies (D.C.B., K.U.S.), Veterinary Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, Pennsylvania; and Department of Pathobiology and Diagnostic Investigations, Diagnostic Center for Population and Animal Health (M.K.), and the Comparative Medicine
| | - Dorothy C. Brown
- From the School of Veterinary Medicine (E.L.K.), Department of Pathobiology (A.C.D.), and Department of Clinical Studies (D.C.B., K.U.S.), Veterinary Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, Pennsylvania; and Department of Pathobiology and Diagnostic Investigations, Diagnostic Center for Population and Animal Health (M.K.), and the Comparative Medicine
| | - Karin U. Sorenmo
- From the School of Veterinary Medicine (E.L.K.), Department of Pathobiology (A.C.D.), and Department of Clinical Studies (D.C.B., K.U.S.), Veterinary Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, Pennsylvania; and Department of Pathobiology and Diagnostic Investigations, Diagnostic Center for Population and Animal Health (M.K.), and the Comparative Medicine
| |
Collapse
|
67
|
Immunohistochemical Profile of 20 Feline Renal Cell Carcinomas. J Comp Pathol 2017; 157:115-125. [DOI: 10.1016/j.jcpa.2017.06.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2017] [Revised: 06/06/2017] [Accepted: 06/12/2017] [Indexed: 01/10/2023]
|
68
|
Cunha S, Corgozinho K, Valga S, Ferreira A. Tratamento de um mastocitoma de alto grau na língua de um cão por meio de radioterapia e quimioterapia: relato de caso. ARQ BRAS MED VET ZOO 2017. [DOI: 10.1590/1678-4162-8331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
RESUMO Um canino da raça Boxer, fêmea, de oito anos de idade, foi atendido com salivação, halitose e disfagia. No exame clínico, foi observada uma massa ulcerada no terço médio da língua medindo 3,5 x 4,0cm. A histopatologia e a imuno-histoquímica levaram ao diagnóstico de um mastocitoma de alto grau. O tratamento cirúrgico (glossectomia parcial) foi declinado pelo proprietário, sendo a radioterapia indicada em seu lugar. O protocolo radioterápico empregado foi 15 frações de 300cGy, realizadas cinco vezes por semana. O equipamento utilizado foi de ortovoltagem. A lesão neoplásica apresentou remissão clínica completa a partir da quarta sessão radioterápica. O único efeito colateral observado foi mucosite leve na região irradiada, que, entretanto, não levou a sintomas clínicos. A quimioterapia sistêmica consistiu de vimblastina e lomustina, alternadas a cada 14 dias, durante quatro meses. Até o momento (22 meses após o tratamento), não há evidências de recidiva local ou metástases do mastocitoma. A associação da radioterapia e da quimioterapia pode ser considerada uma alternativa terapêutica nos casos de mastocitomas irressecáveis, já que, neste caso, levou à remissão completa e duradoura de um tumor agressivo, com ótima tolerância do paciente ao tratamento e posterior qualidade de vida.
Collapse
|
69
|
Halsey CHC, Thamm DH, Weishaar KM, Burton JH, Charles JB, Gustafson DL, Avery AC, Ehrhart EJ. Expression of Phosphorylated KIT in Canine Mast Cell Tumor. Vet Pathol 2017; 54:387-394. [DOI: 10.1177/0300985816688943] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Canine cutaneous mast cell tumor (MCT) is the most common canine skin tumor and exhibits variable biologic behavior. Signaling through the KIT receptor tyrosine kinase promotes cellular proliferation and survival and has been shown to play a role in MCT progression. Despite investigations into numerous biomarkers and the proposal of several grading schemas, no single marker or grading system can accurately predict outcome in canine MCT. The first aim of this study was to develop an immunohistochemical assay to measure phosphorylated KIT (pKIT) to investigate its association with 2 commonly used grading systems and other established prognostic markers for canine MCT. Thirty-four archived MCTs were evaluated for expression of pKIT and Ki-67, KIT localization, mitotic count, mutations in exons 8 and 11 in c-kit, and grading by the Patnaik and 2-tier systems. Expression of pKIT was significantly ( P < .05) correlated with the 2-tier grading scheme and c-kit mutation. Correlation approached significance ( P = .06) with Mitotic Index (MI) and Ki-67. An additional aim was to determine whether pKIT labeling provides a pharmacodynamic marker for predicting response to the receptor tyrosine kinase inhibitor toceranib (TOC). MCTs from 4 of 7 patients demonstrated a partial response to TOC. pKIT expression was assessed by immunohistochemistry in biopsies obtained before and 6 hours after the patients were treated with TOC. Reduced pKIT expression after TOC treatment was demonstrated in 3 of the 4 patients with a partial response compared to 1 of the 3 nonresponders. Collectively, these results demonstrate that immunohistochemical detection of pKIT may be a clinically relevant assay to evaluate the activation status of the major oncogenic pathway in canine MCT.
Collapse
Affiliation(s)
- C. H. C. Halsey
- Cell and Molecular Biology, Colorado State University, Fort Collins, CO, USA
| | - D. H. Thamm
- Cell and Molecular Biology, Colorado State University, Fort Collins, CO, USA
- Department of Clinical Sciences, College of Veterinary Medicine and Biosciences, Colorado State University, Fort Collins, CO, USA
| | - K. M. Weishaar
- Department of Clinical Sciences, College of Veterinary Medicine and Biosciences, Colorado State University, Fort Collins, CO, USA
| | - J. H. Burton
- Department of Surgical & Radiological Sciences, College of Veterinary Medicine, University of California, Davis, CA, USA
| | - J. B. Charles
- Department of Clinical Sciences, College of Veterinary Medicine and Biosciences, Colorado State University, Fort Collins, CO, USA
| | - D. L. Gustafson
- Cell and Molecular Biology, Colorado State University, Fort Collins, CO, USA
- Department of Clinical Sciences, College of Veterinary Medicine and Biosciences, Colorado State University, Fort Collins, CO, USA
| | - A. C. Avery
- Cell and Molecular Biology, Colorado State University, Fort Collins, CO, USA
- Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biosciences, Colorado State University, Fort Collins, CO, USA
| | - E. J. Ehrhart
- Cell and Molecular Biology, Colorado State University, Fort Collins, CO, USA
- Department of Clinical Sciences, College of Veterinary Medicine and Biosciences, Colorado State University, Fort Collins, CO, USA
- Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biosciences, Colorado State University, Fort Collins, CO, USA
| |
Collapse
|
70
|
Vilalta L, Meléndez-Lazo A, Doria G, Ramis A, Solano-Gallego L, Pastor J, Martorell J. Clinical, Cytological, Histological and Immunohistochemical Features of Cutaneous Mast Cell Tumours in Ferrets ( Mustela putorius furo ). J Comp Pathol 2016; 155:346-355. [DOI: 10.1016/j.jcpa.2016.07.012] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2016] [Revised: 07/22/2016] [Accepted: 07/27/2016] [Indexed: 10/21/2022]
|
71
|
Macfarlane MJ, Macfarlane LL, Scase T, Parkin T, Morris JS. Use of neutrophil to lymphocyte ratio for predicting histopathological grade of canine mast cell tumours. Vet Rec 2016; 179:491. [PMID: 27650464 DOI: 10.1136/vr.103650] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/22/2016] [Indexed: 11/04/2022]
Abstract
Canine mast cell tumours (MCTs) are variable in their biological behaviour and treatment decisions depend heavily on the histopathological grade. Biomarkers such as neutrophil to lymphocyte ratio (NLR) and albumin to globulin ratio are used to predict the biological behaviour of human neoplasms, but have not been widely studied in dogs. A retrospective analysis identified 62 cases of gross MCT (14 high-grade, 48 low-grade tumours). Median NLR was significantly different between high- and low-grade MCT and tumours at different locations. A multivariable model identified increasing NLR (OR 2.0) and age (OR 1.7) to be associated with an increased risk of high-grade MCT. Receiver operating characteristic curve analysis identified an NLR threshold value of 5.67 (sensitivity 85.7 per cent; specificity 54.2 per cent) for predicting a high-grade MCT. An NLR threshold of 5.67 could be useful alongside existing tools (appearance, location, etc.) to help to predict the grade of MCT. With further validation, this biomarker could be used to guide clinical decisions before obtaining a histopathological diagnosis.
Collapse
Affiliation(s)
- M J Macfarlane
- University of Glasgow, School of Veterinary Medicine, Glasgow, UK
| | - L L Macfarlane
- University of Glasgow, School of Veterinary Medicine, Glasgow, UK
| | - T Scase
- Bridge Pathology Ltd, Bristol, UK
| | - T Parkin
- University of Glasgow, Institute of Biodiversity Animal Health and Comparative Medicine, Glasgow, UK
| | - J S Morris
- University of Glasgow, School of Veterinary Medicine, Glasgow, UK
| |
Collapse
|
72
|
Wolfesberger B, Fuchs-Baumgartinger A, Hlavaty J, Meyer FR, Hofer M, Steinborn R, Gebhard C, Walter I. Stem cell growth factor receptor in canine vs. feline osteosarcomas. Oncol Lett 2016; 12:2485-2492. [PMID: 27698817 PMCID: PMC5038442 DOI: 10.3892/ol.2016.5006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2015] [Accepted: 07/22/2016] [Indexed: 12/23/2022] Open
Abstract
Osteosarcoma is considered the most common bone cancer in cats and dogs, with cats having a much better prognosis than dogs, since the great majority of dogs with osteosarcoma develop distant metastases. In search of a factor possibly contributing to this disparity, the stem cell growth factor receptor KIT was targeted, and the messenger (m)RNA and protein expression levels of KIT were compared in canine vs. feline osteosarcomas, as well as in normal bone. The mRNA expression of KIT was quantified by reverse transcription-quantitative polymerase chain reaction, and was observed to be significantly higher in canine (n=14) than in feline (n=5) osteosarcoma samples (P<0.001). KIT protein expression was evaluated by immunohistochemistry, which revealed that 21% of canine osteosarcoma samples did not exhibit KIT staining in their neoplastic cells, while in 14% of samples, a score of 1 (<10% positive tumour cells) was observed, and in 50% and 14% of samples, a score of 2 (10–50% positivity) and 3 (>50% positivity), respectively, was observed. By contrast, the cancer cells of all the feline bone tumour samples analysed were entirely negative for KIT. Notably, canine and feline osteocytes of healthy bone tissue lacked any KIT expression. These results could be the first evidence that KIT may be involved in the higher aggressiveness of canine osteosarcoma compared with feline osteosarcoma.
Collapse
Affiliation(s)
- Birgitt Wolfesberger
- Department of Companion Animals and Horses, University of Veterinary Medicine Vienna, A-1210 Vienna, Austria
| | | | - Juraj Hlavaty
- Department of Pathobiology, University of Veterinary Medicine Vienna, A-1210 Vienna, Austria
| | - Florian R Meyer
- Department of Pathobiology, University of Veterinary Medicine Vienna, A-1210 Vienna, Austria
| | - Martin Hofer
- Genomics Core Facility, VetCore, University of Veterinary Medicine Vienna, A-1210 Vienna, Austria
| | - Ralf Steinborn
- Genomics Core Facility, VetCore, University of Veterinary Medicine Vienna, A-1210 Vienna, Austria
| | - Christiane Gebhard
- Department of Pathobiology, University of Veterinary Medicine Vienna, A-1210 Vienna, Austria
| | - Ingrid Walter
- Department of Pathobiology, University of Veterinary Medicine Vienna, A-1210 Vienna, Austria
| |
Collapse
|
73
|
Bauer K, Hadzijusufovic E, Cerny-Reiterer S, Hoermann G, Reifinger M, Pirker A, Valent P, Willmann M. IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells. Vet Comp Oncol 2016; 15:1240-1256. [PMID: 27507155 DOI: 10.1111/vco.12260] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2016] [Revised: 05/24/2016] [Accepted: 07/11/2016] [Indexed: 12/15/2022]
Abstract
CD30 is a novel therapeutic target in human mast cell (MC) neoplasms. In this 'comparative oncology' study, we examined CD30 expression and regulation in neoplastic canine MC using a panel of immunomodulatory cytokines [interleukin-2 (IL-2), IL-4, IL-5, IL-6, IL-13 and stem cell factor (SCF)] and the canine mastocytoma cell lines NI-1 and C2. Of all cytokines tested IL-4 was found to downregulate expression of CD30 in NI-1 and C2 cells. We also found that the CD30-targeting antibody-conjugate brentuximab vedotin induces growth inhibition and apoptosis in both MC lines. Next, we asked whether IL-4-induced downregulation of CD30 interferes with brentuximab vedotin-effects. Indeed, pre-incubation of NI-1 cells with IL-4 decreased responsiveness towards brentuximab vedotin. To overcome IL-4-mediated resistance, we applied drug combinations and found that brentuximab vedotin synergizes with the Kit-targeting drugs masitinib and PKC412 in inhibiting growth of NI-1 and C2 cells. In summary, CD30 is a new marker and IL-4-regulated target in neoplastic canine MC.
Collapse
Affiliation(s)
- K Bauer
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
| | - E Hadzijusufovic
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.,Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria.,Department/Clinic for Companion Animals and Horses, Clinic for Small Animals, Clinical Unit of Internal Medicine, University of Veterinary Medicine Vienna, Vienna, Austria
| | - S Cerny-Reiterer
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.,Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria
| | - G Hoermann
- Department for Laboratory Medicine, Medical University of Vienna, Vienna, Austria
| | - M Reifinger
- Department of Pathobiology, University of Veterinary Medicine Vienna, Vienna, Austria
| | - A Pirker
- Department/Clinic for Companion Animals and Horses, Clinic for Small Animals, Clinical Unit of Surgery, University of Veterinary Medicine Vienna, Vienna, Austria
| | - P Valent
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.,Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria
| | - M Willmann
- Department/Clinic for Companion Animals and Horses, Clinic for Small Animals, Clinical Unit of Internal Medicine, University of Veterinary Medicine Vienna, Vienna, Austria
| |
Collapse
|
74
|
Webster JD. Transcriptional profiling of canine mast cell tumors: Searching for candidate targets and prognostic markers. Vet J 2016; 214:84-5. [PMID: 27387731 DOI: 10.1016/j.tvjl.2016.05.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2016] [Accepted: 05/31/2016] [Indexed: 11/17/2022]
Affiliation(s)
- Joshua D Webster
- Department of Pathology, Genentech, South San Francisco, CA 90480, USA.
| |
Collapse
|
75
|
Seeliger F, Hess O, Pröpsting MJ, Pröbsting M, Naim HY, Kleinschmidt S, Woehrmann T, Germann PG, Baumgärtner W. Confocal Laser Scanning Analysis of an Equine Oral Mast Cell Tumor with Atypical Expression of Tyrosine Kinase Receptor C-KIT. Vet Pathol 2016; 44:225-8. [PMID: 17317803 DOI: 10.1354/vp.44-2-225] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
A 20-year-old female horse showed a nodular, firm, focal ulcerated mast cell tumor at the right dorsobuccal face of the tongue. Histologically, the nonencapsulated tumor consisted of dense, infiltrating aggregates of well-differentiated, Cresyl violet-positive mast cells accompanied by numerous eosinophils. Furthermore, they exhibited a strong, diffuse, intracytoplasmatic immunohistochemical signal for tryptase and a faint membrane-associated and perinuclear signal for tyrosine kinase receptor KIT. Confocal laser scanning microscopy confirmed an aberrant spatial colocalization of KIT in the Golgi apparatus, which may be the result of a defective protein processing within the tumor cells. The tumor was not associated with a poor prognosis.
Collapse
Affiliation(s)
- F Seeliger
- Department of Pathology, University of Veterinary Medicine Hannover, Hannover, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
76
|
Webster JD, Yuzbasiyan-Gurkan V, Miller RA, Kaneene JB, Kiupel M. Cellular Proliferation in Canine Cutaneous Mast Cell Tumors: Associations with c-KIT and Its Role in Prognostication. Vet Pathol 2016; 44:298-308. [PMID: 17491070 DOI: 10.1354/vp.44-3-298] [Citation(s) in RCA: 142] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Canine cutaneous mast cell tumor (MCT) is a common neoplastic disease in dogs. Due to the prevalence of canine MCTs and the variable biologic behavior of this disease, accurate prognostication and a thorough understanding of MCT biology are critical for the treatment of this disease. The goals of this study were to evaluate and compare the utility of the proliferation markers Ki67, proliferating cell nuclear antigen (PCNA), and argyrophilic nucleolar organizing region (AgNOR) as independent prognostic markers for canine MCTs and to evaluate the use of these markers in combination, as each marker assesses different aspects of cellular proliferation. An additional goal of this study was to evaluate the associations between cellular proliferation and c-KIT mutations and between cellular proliferation and aberrant KIT protein localization in canine MCTs. Fifty-six MCTs treated with surgical excision alone were included in this study. Each MCT was evaluated for Ki67 expression, PCNA expression, and KIT protein localization using immunohistochemistry; for AgNOR counts using histochemical staining; and for the presence of internal tandem duplication c-KIT mutations using polymerase chain reaction amplification. In this study, increased Ki67 and AgNOR counts were both associated with significantly decreased survival. On the basis of these results, we recommend that the evaluation of cellular proliferation, including evaluations of both Ki67 expression and AgNORs, should be routinely used in the prognostication of canine MCTs. Additionally, the results of this study show that MCTs with aberrant KIT protein localization or internal tandem duplication c-KIT mutations are associated with increased cellular proliferation, further suggesting a role for c-KIT in the progression of canine MCTs.
Collapse
Affiliation(s)
- J D Webster
- Comparative Medicine and Integrative Biology Program, Michigan State University, Lansing, MI 48910, USA
| | | | | | | | | |
Collapse
|
77
|
Northrup NC, Howerth EW, Harmon BG, Brown CA, Carmicheal KP, Garcia AP, Latimer KS, Munday JS, Rakich PM, Richey LJ, Stedman NL, Gieger TL. Variation among Pathologists in the Histologic Grading of Canine Cutaneous Mast Cell Tumors with Uniform Use of a Single Grading Reference. J Vet Diagn Invest 2016; 17:561-4. [PMID: 16475514 DOI: 10.1177/104063870501700606] [Citation(s) in RCA: 61] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Ten veterinary pathologists independently assigned histologic grades to the same 60 canine cutaneous mast cell tumors using the Patnaik classifications. The degree of agreement in grading among the pathologists was compared with the degree of agreement among the same pathologists in a previous study, in which each pathologist used the reference for grading that he/she uses routinely. Mean agreement improved significantly from 50.3% to 62.1% with uniform use of the Patnaik classifications ( P = 0.00001), suggesting that there is value in uniform application of a single grading scheme for canine cutaneous mast cell tumors. Agreement among pathologists was still not 100%, suggesting that a more objective grading scheme should be developed and that other histologic indicators of prognosis should be investigated.
Collapse
Affiliation(s)
- N C Northrup
- Department of Small Animal Medicine and Surgery, Comparative Oncology Program, University of Georgia, College of Veterinary Medicine, Athens 30602, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
78
|
Sledge DG, Webster J, Kiupel M. Canine cutaneous mast cell tumors: A combined clinical and pathologic approach to diagnosis, prognosis, and treatment selection. Vet J 2016; 215:43-54. [PMID: 27372911 DOI: 10.1016/j.tvjl.2016.06.003] [Citation(s) in RCA: 66] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2016] [Revised: 05/25/2016] [Accepted: 06/12/2016] [Indexed: 12/20/2022]
Abstract
In view of the varied biologic behavior and the costs of treatment for canine cutaneous mast cell tumors, development of appropriate treatment plans for individual affected dogs can be difficult, but decisions regarding treatment should be made using a systematic, evidence-based approach. This manuscript reviews the current state of diagnostics and prognostication of canine cutaneous mast cell tumors, and suggests a combined approach based on clinical and pathologic assessment for decision making regarding treatment choices. The current state of histologic grading, evaluation of proliferation indices, evaluation of mutations in the c-kit gene and KIT expression, evaluation of excision and clinical staging are examined. On the basis of the current understanding of prognostication and treatment response, algorithms for selection of local and systemic therapy are presented.
Collapse
Affiliation(s)
- Dodd G Sledge
- Diagnostic Center for Population and Animal Health, Michigan State University, 4125 Beaumont Road, Lansing, MI 48910, USA.
| | - Joshua Webster
- Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
| | - Matti Kiupel
- Diagnostic Center for Population and Animal Health, Michigan State University, 4125 Beaumont Road, Lansing, MI 48910, USA
| |
Collapse
|
79
|
Milovancev M, Helfand SC, Marley K, Goodall CP, Löhr CV, Bracha S. Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro. BMC Vet Res 2016; 12:85. [PMID: 27259510 PMCID: PMC4893279 DOI: 10.1186/s12917-016-0712-x] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2015] [Accepted: 05/30/2016] [Indexed: 01/26/2023] Open
Abstract
Background Canine oral fibrosarcoma (COF) is one of the most common oral tumors in dogs and carries a guarded prognosis due to a lack of effective systemic therapeutic options. Mastinib and imatinib are two commonly used tyrosine kinase inhibitors (TKIs) in veterinary oncology but their potential efficacy against COF is uncharacterized. To begin investigating the rationale for use of these TKIs against COF, the present study tested for the presence TKI targets PDGFR-α, PDGFR-β, Kit, and VEGFR-2 and examined the in vitro effects on cell viability after TKI treatment alone or with doxorubicin. Immunohistochemistry for PDGFR-α, PDGFR-β, Kit, and VEGFR-2 was performed in 6 COF tumor biopsies. Presence of these same receptors within 2 COF cell lines was probed by reverse transcription-polymerase chain reaction and, for those with mRNA detected, confirmed via western blot. Effects on cell viability were assessed using an MTS assay after masitinib or imatinib treatment alone (0-100 μM), or in combination with doxorubicin (0-3000 nM doxorubicin). Anti-PDGFRB siRNA knockdown was performed and the effect on cell viability quantified. Results Expression of the TKI targets evaluated was similar between the 2 COF cell lines and the 6 COF tumor biopsies: PDGFR-α and PDGFR-β were detected in neoplastic cells from most COF tumor biopsies (5/6 and 6/6, respectively) and were present in both COF cell lines; KIT and KDR were not detected in any sample. Masitinib and imatinib IC50 values ranged from 7.9–33.4 μM, depending on the specific TKI and cell line tested. The addition of doxorubicin resulted in synergistic cytotoxicity with both TKIs. Anti-PDGFRB siRNA transfection reduced PDGFR-β protein expression by 77 % and 67 % and reduced cell viability by 24 % (p < 0.0001) and 28 % (0 = 0.0003) in the two cell lines, respectively. Conclusions These results provide rationale for further investigation into the use of TKIs, possibly in combination with doxorubicin, as treatment options for COF.
Collapse
Affiliation(s)
- Milan Milovancev
- Department of Clinical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, OR, 97331, USA.
| | - Stuart C Helfand
- Department of Clinical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, OR, 97331, USA
| | - Kevin Marley
- Department of Clinical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, OR, 97331, USA
| | - Cheri P Goodall
- Department of Clinical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, OR, 97331, USA
| | - Christiane V Löhr
- Department of Biomedical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, OR, 97331, USA
| | - Shay Bracha
- Department of Clinical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, OR, 97331, USA
| |
Collapse
|
80
|
Junginger J, Geburek F, Khan MA, Müller G, Gruber AD, Hewicker-Trautwein M. Cutaneous form of maculopapular mastocytosis in a foal. Vet Dermatol 2016; 27:202-e51. [PMID: 27109586 DOI: 10.1111/vde.12308] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/06/2016] [Indexed: 12/01/2022]
Abstract
BACKGROUND Cutaneous mastocytosis is a rare benign disease occurring in domestic animals and humans. In previous reports, dermal findings in foals were accompanied by systemic mast cell infiltrations, whereas lesions in human cutaneous mastocytosis, including urticaria pigmentosa and solitary mastocytoma, are usually restricted to the skin. OBJECTIVES To describe a new variant of equine cutaneous maculopapular mastocytosis lacking systemic involvement. ANIMALS A 2.5-month-old warmblood foal with multiple skin nodules since birth. METHODS Clinical examination (including haematology, fine needle biopsy and thoracic radiographs), postmortem examination, histopathology and immunohistochemistry. RESULTS Clinical examination showed 41 skin nodules that contained numerous mast cells as detected by cytology. Macroscopic examination at postmortem examination revealed intradermal circumscribed lesions ranging from 2 to 5 cm in diameter. Histologically, they were composed of well differentiated mast cells with metachromatic granules stained with toluidine blue accompanied by many eosinophils. Immunohistochemically, mast cells had mast cell growth factor receptor c-KIT predominating at the cell surface and intracytoplasmic expression of tryptase. In other organs similar mast cell infiltrations were not detected. CONCLUSIONS AND CLINICAL IMPORTANCE The case presented here fulfils the criteria of equine cutaneous maculopapular mastocytosis (ECMM), representing a rare entity in foals that is reported to be associated with spontaneous regression, although the long-term prognosis is not known. Unlike in previous reports, lesions described here were restricted to the skin. This may imply that ECMM is primarily a dermal disease sharing similarities with urticaria pigmentosa in young children.
Collapse
Affiliation(s)
- Johannes Junginger
- Department of Pathology, University of Veterinary Medicine, Bünteweg 17, D-30559, Hannover, Germany
| | - Florian Geburek
- Clinic for Horses, University of Veterinary Medicine, Bünteweg 9, D-30559, Hannover, Germany
| | - Muhammad Akram Khan
- Department of Pathology, University of Veterinary Medicine, Bünteweg 17, D-30559, Hannover, Germany
| | - Gundi Müller
- Non-clinical safety, Global early development, Merck KGaA, Frankfurter Straße 250, D-64293, Darmstadt, Germany
| | - Achim D Gruber
- Department of Veterinary Pathology, Freie Universität Berlin, Robert-von-Ostertag-Str. 15, D-14163, Berlin, Germany
| | | |
Collapse
|
81
|
Pulz LH, Barra CN, Kleeb SR, Xavier JG, Catão-Dias JL, Sobral RA, Fukumasu H, Strefezzi RF. Increased expression of tissue inhibitor of metalloproteinase-1 correlates with improved outcome in canine cutaneous mast cell tumours. Vet Comp Oncol 2016; 15:606-614. [PMID: 27041588 DOI: 10.1111/vco.12204] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2015] [Accepted: 11/29/2015] [Indexed: 01/21/2023]
Abstract
Canine mast cell tumour (MCT) is a biologically heterogeneous disease. The extracellular matrix degradation promoted by matrix metalloproteinases (MMPs) has been studied in an attempt to elucidate the mechanisms involved in the biological behaviour of tumours. The aim of this study was to characterize the expression of MMP-2 and -9 and tissue inhibitors of metalloproteinase (TIMP)-1 and -2 in canine cutaneous MCTs and to evaluate their prognostic values. Immunohistochemical staining for MMP-2, MMP-9, TIMP-2 and TIMP-1 was performed in 46 canine cases of MCTs. TIMP-1 expression showed an independent prognostic value for post-surgical survival and disease-related mortality. Dogs with MCTs showing less than 22.9% mast cell TIMP-1 positivity were more prone to die because of the disease and had a shorter post-surgical survival. This article suggests the involvement of TIMP-1 in MCT progression, by contributing to a good outcome in patients with MCTs.
Collapse
Affiliation(s)
- L H Pulz
- Departamento de Patologia, Faculdade de Medicina Veterinária e Zootecnia, Universidade de São Paulo, São Paulo, Brazil.,Laboratório de Oncologia Comparada e Translacional, Faculdade de Zootecnia e Engenharia de Alimentos, Universidade de São Paulo, Pirassununga, Brazil
| | - C N Barra
- Departamento de Patologia, Faculdade de Medicina Veterinária e Zootecnia, Universidade de São Paulo, São Paulo, Brazil.,Laboratório de Oncologia Comparada e Translacional, Faculdade de Zootecnia e Engenharia de Alimentos, Universidade de São Paulo, Pirassununga, Brazil
| | - S R Kleeb
- Universidade Metodista de São Paulo, São Bernardo do Campo, Brazil
| | - J G Xavier
- Universidade Paulista, São Paulo, Brazil
| | - J L Catão-Dias
- Departamento de Patologia, Faculdade de Medicina Veterinária e Zootecnia, Universidade de São Paulo, São Paulo, Brazil
| | - R A Sobral
- Onco Cane Veterinária, São Paulo, Brazil
| | - H Fukumasu
- Laboratório de Oncologia Comparada e Translacional, Faculdade de Zootecnia e Engenharia de Alimentos, Universidade de São Paulo, Pirassununga, Brazil
| | - R F Strefezzi
- Laboratório de Oncologia Comparada e Translacional, Faculdade de Zootecnia e Engenharia de Alimentos, Universidade de São Paulo, Pirassununga, Brazil
| |
Collapse
|
82
|
Giantin M, Baratto C, Marconato L, Vascellari M, Mutinelli F, Dacasto M, Granato A. Transcriptomic analysis identified up-regulation of a solute carrier transporter and UDP glucuronosyltransferases in dogs with aggressive cutaneous mast cell tumours. Vet J 2016; 212:36-43. [PMID: 27256023 DOI: 10.1016/j.tvjl.2016.03.024] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2015] [Revised: 03/10/2016] [Accepted: 03/27/2016] [Indexed: 11/17/2022]
Abstract
Gene expression analyses have been recently used in cancer research to identify genes associated with tumorigenesis and potential prognostic markers or therapeutic targets. In the present study, the transcriptome of dogs that had died because of mast cell tumours (MCTs) was characterised to identify a fingerprint having significant influence on prognosis determination and treatment selection. A dataset (GSE50433) obtained using a commercial canine DNA microarray platform was used. The transcriptome of seven biopsies obtained from dogs with histologically confirmed, surgically removed MCTs, treated with chemotherapy, and dead for MCT-related causes, was compared with the transcriptional portrait of 40 samples obtained from dogs with histologically confirmed, surgically removed MCTs and that were still alive at the end of the follow-up period. Among the differentially expressed genes (DEGs), eight transcripts were validated by quantitative real time PCR and their mRNA levels were measured in a cohort of 22 additional MCTs. Statistical analysis identified 375 DEGs (fold change 2, false discovery rate 5%). The functional annotation analysis indicated that the DEGs were associated with drug metabolism and cell cycle pathways. Particularly, members of solute carrier transporter (SLC) and UDP glucuronosyltransferase (UGT) gene families were identified as dysregulated. Principal component analysis (PCA) of the 22 additional MCTs identified the separate cluster dogs dead for MCT-related causes. SLCs and UGTs have been recently recognised in human cancer as important key factors in tumour progression and chemo-resistance. An in-depth analysis of their roles in aggressive canine MCT is warranted in future studies.
Collapse
Affiliation(s)
- Mery Giantin
- Dipartimento di Biomedicina Comparata e Alimentazione, Università degli Studi di Padova, Viale dell'Università 16, I-35020 Agripolis Legnaro (Padova), Italy.
| | - Chiara Baratto
- Istituto Zooprofilattico Sperimentale delle Venezie, Viale dell'Università 10, I-35020 Legnaro (Padova), Italy
| | - Laura Marconato
- Centro Oncologico Veterinario, Via San Lorenzo 1/4, I-40037 Sasso Marconi (Bologna), Italy
| | - Marta Vascellari
- Istituto Zooprofilattico Sperimentale delle Venezie, Viale dell'Università 10, I-35020 Legnaro (Padova), Italy
| | - Franco Mutinelli
- Istituto Zooprofilattico Sperimentale delle Venezie, Viale dell'Università 10, I-35020 Legnaro (Padova), Italy
| | - Mauro Dacasto
- Dipartimento di Biomedicina Comparata e Alimentazione, Università degli Studi di Padova, Viale dell'Università 16, I-35020 Agripolis Legnaro (Padova), Italy
| | - Anna Granato
- Istituto Zooprofilattico Sperimentale delle Venezie, Viale dell'Università 10, I-35020 Legnaro (Padova), Italy
| |
Collapse
|
83
|
Advanced Diagnostic Techniques. CANINE AND FELINE CYTOLOGY 2016. [PMCID: PMC7158337 DOI: 10.1016/b978-1-4557-4083-3.00017-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 09/24/2023]
|
84
|
Vargas T, Pulz L, Barra C, Kleeb S, Xavier J, Catão-Dias J, Fukumasu H, Nishiya A, Strefezzi R. Immunohistochemical Expression of the Pluripotency Factor OCT4 in Canine Mast Cell Tumours. J Comp Pathol 2015; 153:251-5. [DOI: 10.1016/j.jcpa.2015.08.010] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2015] [Revised: 08/28/2015] [Accepted: 08/31/2015] [Indexed: 12/13/2022]
|
85
|
Evaluation of Minichromosome Maintenance Protein 7 and c-KIT as Prognostic Markers in Feline Cutaneous Mast Cell Tumours. J Comp Pathol 2015; 153:244-50. [PMID: 26385324 DOI: 10.1016/j.jcpa.2015.08.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2015] [Revised: 08/11/2015] [Accepted: 08/18/2015] [Indexed: 12/31/2022]
Abstract
Mast cell tumours (MCTs) are a common skin tumour in cats, but there is currently no histological grading system or reliable prognostic marker for this species (unlike the situation for dogs). This study utilized a set of 71 feline cutaneous MCTs with known clinical outcomes to assess the potential of various prognostic markers, including the cellular proliferation marker minichromosome maintenance protein (MCM)-7, mitotic index and various KIT labelling characteristics, including KIT positivity, KIT labelling pattern and KIT immunoreactivity score (IS). Of the factors studied, the mitotic index and the KIT labelling pattern were the only features associated significantly with survival times, while the proliferation marker MCM7 and the KIT IS were not. The study also highlights the variability of KIT labelling characteristics between tumours, which may prevent use of this marker as a diagnostic and prognostic tool.
Collapse
|
86
|
Ressel L, Ward S, Kipar A. Equine Cutaneous Mast Cell Tumours Exhibit Variable Differentiation, Proliferation Activity and KIT Expression. J Comp Pathol 2015; 153:236-43. [PMID: 26292768 DOI: 10.1016/j.jcpa.2015.07.006] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2015] [Revised: 06/13/2015] [Accepted: 07/16/2015] [Indexed: 11/28/2022]
Abstract
Equine cutaneous mast cell tumours (CMCTs) are generally considered to be benign skin lesions, although recurrent and multicentric tumours have been described. For canine CMCTs, grading and prognostic approaches are well established and aberrant KIT expression as well as high proliferation indices are associated with poor outcome. However, in the case of equine CMCTs, morphological features, proliferative activity and KIT expression pattern have not been assessed or related to biological behaviour, and there is discussion as to whether CMCTs are true neoplastic processes. The present study describes 45 equine CMCTs in terms of their morphology and KIT and PCNA expression by immunohistochemistry. KIT expression was classified as membranous (I), cytoplasmic and focally stippled (II) or diffuse cytoplasmic (III). A large proportion of the tumours were multinodular or diffuse dermal infiltrates of mast cells with mild anisokaryosis, a low proliferative rate and a dominance of KIT pattern I, representing well-differentiated CMCTs. In approximately one third of the cases, the mast cells exhibited more infiltrative growth, moderate to marked anisokaryosis and a higher degree of proliferation. These were classified as poorly differentiated CMCTs and exhibited only KIT patterns II and III. These findings indicate that there is a subgroup of poorly differentiated equine CMCTs, in which there is an association between aberrant KIT expression, high proliferative rate and potential aggressive behaviour, all features that confirm at least the poorly differentiated CMCT as a true neoplastic processes.
Collapse
Affiliation(s)
- L Ressel
- Division of Veterinary Pathology, School of Veterinary Science, University of Liverpool, Leahurst Campus, Chester High Road, Neston, UK.
| | - S Ward
- Division of Veterinary Pathology, School of Veterinary Science, University of Liverpool, Leahurst Campus, Chester High Road, Neston, UK
| | - A Kipar
- Division of Veterinary Pathology, School of Veterinary Science, University of Liverpool, Leahurst Campus, Chester High Road, Neston, UK; Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 268, Zurich, Switzerland
| |
Collapse
|
87
|
Fonseca-Alves CE, Bento DD, Torres-Neto R, Werner J, Kitchell B, Laufer-Amorim R. Ki67/KIT double immunohistochemical staining in cutaneous mast cell tumors from Boxer dogs. Res Vet Sci 2015; 102:122-6. [PMID: 26412531 DOI: 10.1016/j.rvsc.2015.08.007] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2015] [Revised: 07/16/2015] [Accepted: 08/06/2015] [Indexed: 12/11/2022]
Abstract
Cutaneous mast cell tumors (MCTs) are among the most frequent malignant tumors in dogs and Boxer breed dogs have a higher incidence of this disease. Ki67 staining and KIT staining are widely used to predict natural behavior in canine MCT but no previous study has evaluated double staining of these proteins as a prognostic factor. Based on biological behavior predictors in canine MCT, the purpose of this study was to determine the Ki67 proliferative index in KIT positive cells using double stain immunohistochemistry technique. Sixty-nine MCTs from Boxer dogs were selected and a tissue microarray was constructed for the double stained immunohistochemistry. Double positivity (Ki67(+)/KIT(+)) was observed in 20/69 (29%) MCT, with a mean of 9.06 double positive cells per tissue core (range 0.48%-43.97%) and Ki67(-)/KIT(+) animals had a longer survival time than Ki67(+)/KIT(+) animals (p=0.03).
Collapse
Affiliation(s)
- Carlos Eduardo Fonseca-Alves
- Veterinary Clinic Department, School of Veterinary Medicine and Animal Science, Univ Estadual Paulista, UNESP, Botucatu, SP, Brazil
| | - Daniel Diola Bento
- Veterinary Clinic Department, School of Veterinary Medicine and Animal Science, Univ Estadual Paulista, UNESP, Botucatu, SP, Brazil
| | - Rafael Torres-Neto
- Veterinary Clinic Department, School of Veterinary Medicine and Animal Science, Univ Estadual Paulista, UNESP, Botucatu, SP, Brazil
| | | | | | - Renée Laufer-Amorim
- Veterinary Clinic Department, School of Veterinary Medicine and Animal Science, Univ Estadual Paulista, UNESP, Botucatu, SP, Brazil.
| |
Collapse
|
88
|
Gil da Costa RM. C-kit as a prognostic and therapeutic marker in canine cutaneous mast cell tumours: From laboratory to clinic. Vet J 2015; 205:5-10. [PMID: 26021891 DOI: 10.1016/j.tvjl.2015.05.002] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2015] [Revised: 04/29/2015] [Accepted: 05/02/2015] [Indexed: 12/28/2022]
Abstract
Cutaneous mast cell tumours (MCTs) are some of the most common canine neoplasms and their variable and often aggressive biological behaviour makes them particularly challenging for the veterinary practitioner. Over the years, scientists have accumulated a wealth of knowledge on these tumours and developed better prognostic markers and targeted therapies, mostly focused on inhibiting c-kit, a protein that plays a major role in the biopathology of MCTs. Masitinib and toceranib, targeted inhibitors of c-kit and other receptor tyrosine-kinases (RTKs), offer the promise of improving the outcome of patients with aggressive MCTs. Much of the available knowledge on MCTs is dispersed, making it difficult for practitioners to benefit when consulting a pathologist or making therapeutic decisions. This article seeks to bring together current knowledge on the biopathology of MCTs, reviewing prognostic markers and their applications, and the development of c-kit inhibitors in the context of the basic cellular, molecular and pathological features of MCTs. Future perspectives following recent biopathological data and experimental therapeutic approaches are also addressed.
Collapse
Affiliation(s)
- Rui M Gil da Costa
- Laboratório de Engenharia de Processos, Ambiente, Biotecnologia e Energia (LEPABE), Departamento de Engenharia Química, Faculdade de Engenharia, Universidade do Porto, Rua Dr. Roberto Frias, Porto, Portugal.
| |
Collapse
|
89
|
Kandefer-Gola M, Nowak M, Madej J, Dzimira S, Ciaputa R, Janus I. Useful immunohistochemical indicators in canine mast cell tumours. Acta Vet Hung 2015; 63:49-59. [PMID: 25655414 DOI: 10.1556/avet.2015.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Morphological and immunohistochemical analysis of 45 canine mast cell tumours was performed to determine whether the proteins examined are useful for a more precise description of tumour morphology and a more reliable determination of the prognosis in patients. Tissue sections were stained according to the standard haematoxylin and eosin (HE) technique and with toluidine blue to demonstrate cytoplasmic granules. Immunohistochemical studies were performed, using the cell markers CD117 (c-kit), p16 and von Willebrand factor (FVIII). In CD117 three different staining patterns were observed: (1) membranous reaction, (2) intense staining of cytoplasm, and (3) a diffuse, delicate cytoplasmic reaction. Von Willebrand antibody was evaluated on the basis of the number of blood vessels stained. p16 expression was evaluated by scoring positive nuclear reaction. Positive expression was demonstrated for all examined antigens, but their level of expression differed depending on the grades of tumour malignancy. Statistical analysis of the results documented a pronounced positive correlation between the markers studied and the grade of tumour malignancy (P < 0.001). It was shown that each of the cell markers examined represents a useful prognostic indicator for patients with mast cell tumours. The calculated correlation coefficients demonstrate a strong association between the expressions of CD117, FVIII and p16, and the histological malignancy of a tumour.
Collapse
Affiliation(s)
- Małgorzata Kandefer-Gola
- 1 Wroclaw University of Environmental and Life Sciences Department of Pathology, Faculty of Veterinary Medicine ul. C. K. Norwida 31 50-375 Wroclaw Poland
| | - Marcin Nowak
- 1 Wroclaw University of Environmental and Life Sciences Department of Pathology, Faculty of Veterinary Medicine ul. C. K. Norwida 31 50-375 Wroclaw Poland
| | - Janusz Madej
- 1 Wroclaw University of Environmental and Life Sciences Department of Pathology, Faculty of Veterinary Medicine ul. C. K. Norwida 31 50-375 Wroclaw Poland
| | - Stanisław Dzimira
- 1 Wroclaw University of Environmental and Life Sciences Department of Pathology, Faculty of Veterinary Medicine ul. C. K. Norwida 31 50-375 Wroclaw Poland
| | - Rafal Ciaputa
- 1 Wroclaw University of Environmental and Life Sciences Department of Pathology, Faculty of Veterinary Medicine ul. C. K. Norwida 31 50-375 Wroclaw Poland
| | - Izabela Janus
- 1 Wroclaw University of Environmental and Life Sciences Department of Pathology, Faculty of Veterinary Medicine ul. C. K. Norwida 31 50-375 Wroclaw Poland
| |
Collapse
|
90
|
Ranieri G, Marech I, Pantaleo M, Piccinno M, Roncetti M, Mutinati M, Rizzo A, Gadaleta CD, Introna M, Patruno R, Sciorsci RL. In vivo model for mastocytosis: A comparative review. Crit Rev Oncol Hematol 2014; 93:159-69. [PMID: 25465741 DOI: 10.1016/j.critrevonc.2014.10.010] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2014] [Revised: 10/01/2014] [Accepted: 10/22/2014] [Indexed: 12/27/2022] Open
Abstract
Human mastocytosis are heterogeneous group of neoplastic diseases characterized by a different degree of uncontrolled mast cell (MC) proliferation and activation. Interestingly, human mastocytosis share several biological and clinical features with canine mast cell disorders, so called canine mast cell tumors (CMCTs). These CMCTs are the most common spontaneous cutaneous tumors found in dogs representing a valid model to study neoplastic mast cell disorders. It has been discovered that the pathological activation of c-Kit receptor (c-KitR), expressed by MCs, has been involved in the pathogenesis of neoplastic MC disorders. In this review we have focused on human mastocytosis in terms of: (i) epidemiology and classification; (ii) pathogenesis at molecular levels; (iii) clinical presentation. In addition, we have summarized animal models useful to study neoplastic MC disorders including CMCTs and murine transgenic models. Finally, we have revised therapeutic approaches mostly common in human and canine MCTs and novel tyrosine kinase inhibitors approved for CMCTs and recently translated in human clinical trials.
Collapse
Affiliation(s)
- Girolamo Ranieri
- Diagnostic and Interventional Radiology Unit with Integrated Section of Translational Medical Oncology, National Cancer Research Centre Istituto Tumori "Giovanni Paolo II", Bari, Italy.
| | - Ilaria Marech
- Diagnostic and Interventional Radiology Unit with Integrated Section of Translational Medical Oncology, National Cancer Research Centre Istituto Tumori "Giovanni Paolo II", Bari, Italy
| | - Marianna Pantaleo
- Department of Emergency and Organ Transplantation (D.E.T.O.), Veterinary Medical School, Università "Aldo Moro", Bari, Italy
| | - Mariagrazia Piccinno
- Department of Emergency and Organ Transplantation (D.E.T.O.), Veterinary Medical School, Università "Aldo Moro", Bari, Italy
| | - Maria Roncetti
- Department of Emergency and Organ Transplantation (D.E.T.O.), Veterinary Medical School, Università "Aldo Moro", Bari, Italy
| | - Maddalena Mutinati
- Department of Emergency and Organ Transplantation (D.E.T.O.), Veterinary Medical School, Università "Aldo Moro", Bari, Italy
| | - Annalisa Rizzo
- Department of Emergency and Organ Transplantation (D.E.T.O.), Veterinary Medical School, Università "Aldo Moro", Bari, Italy
| | - Cosmo Damiano Gadaleta
- Diagnostic and Interventional Radiology Unit with Integrated Section of Translational Medical Oncology, National Cancer Research Centre Istituto Tumori "Giovanni Paolo II", Bari, Italy
| | - Marcello Introna
- Department of Pathology, Veterinary Medical School, Università "Aldo Moro", Bari, Italy
| | - Rosa Patruno
- Department of Prevention and Animal Health, ASL BAT, Barletta, Italy
| | - Raffaele Luigi Sciorsci
- Department of Emergency and Organ Transplantation (D.E.T.O.), Veterinary Medical School, Università "Aldo Moro", Bari, Italy
| |
Collapse
|
91
|
Hosseini E, Pedram B, Bahrami AM, Touni SR, Malayeri HZ, Mokarizadeh A, Pourzaer M, Pourzaer M, Zehtabian S, Mohajer S, Ahmadi S. RETRACTED ARTICLE: Diagnostic procedures for improving of the KIT (CD117) expressed allele burden for the liver metastases from uterus mast cell tumors: prognostic value of the metastatic pattern and tumor biology. Tumour Biol 2014; 36:929-37. [DOI: 10.1007/s13277-014-2666-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2014] [Accepted: 09/19/2014] [Indexed: 11/28/2022] Open
|
92
|
Pratschke KM, Atherton MJ, Sillito JA, Lamm CG. Evaluation of a modified proportional margins approach for surgical resection of mast cell tumors in dogs: 40 cases (2008-2012). J Am Vet Med Assoc 2014; 243:1436-41. [PMID: 24171373 DOI: 10.2460/javma.243.10.1436] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To evaluate a modified proportional margins approach to resection of mast cell tumors (MCTs) in dogs. DESIGN Retrospective case series. ANIMALS 40 dogs with subcutaneous and cutaneous MCTs undergoing curative intent surgery. PROCEDURES Medical records were searched to identify dogs with a cytologically or histologically confirmed diagnosis of MCT that had not previously been treated surgically and that had undergone full oncological staging. In those dogs, tumors were resected with lateral margins equivalent to the widest measured diameter of the tumor and a minimum depth of 1 well-defined fascial plane deep to the tumor. Surgical margins were evaluated histologically. Cutaneous tumors were graded by use of the Patnaik system and the 2-tier system described by Kiupel et al. The prognosis for subcutaneous tumors was assessed in accordance with published recommendations. Follow-up information on dog health status was obtained through clinical examination, the dog owners, and the referring veterinarians. RESULTS The 40 dogs had 47 tumors. Forty-one (87%) tumors were cutaneous, and 6 (13%) were subcutaneous. On the basis of the Patnaik system, 21 (51%) cutaneous tumors were considered grade I, 18 (44%) were considered grade II, and 2 (5%) were considered grade III. On the basis of the Kiupel system, 37 (90%) cutaneous tumors were considered low grade, and 4 (10%) were considered high grade. The prognosis for the 6 subcutaneous tumors was classified as likely resulting in a shorter (2) or longer (4) survival time. Forty tumors were deemed to have been excised with clear margins and 7 with incomplete margins. Local recurrence was not recorded for any dog but was suspected for 1 (2%) tumor, although not confirmed. Interval from tumor excision to follow-up ranged from 30 to 1,140 days (median, 420 days). CONCLUSIONS AND CLINICAL RELEVANCE The modified proportional margins system resulted in satisfactory local disease control in dogs with MCTs.
Collapse
Affiliation(s)
- Kathryn M Pratschke
- School of Veterinary Medicine, College of Medical and Veterinary Life Sciences, University of Glasgow, Glasgow, G61 1QH, Scotland
| | | | | | | |
Collapse
|
93
|
Halsey CHC, Gustafson DL, Rose BJ, Wolf-Ringwall A, Burnett RC, Duval DL, Avery AC, Thamm DH. Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor. BMC Vet Res 2014; 10:105. [PMID: 24885200 PMCID: PMC4049511 DOI: 10.1186/1746-6148-10-105] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2014] [Accepted: 04/29/2014] [Indexed: 01/28/2023] Open
Abstract
Background Mast cell tumors (MCTs) are the most common skin tumors in dogs and exhibit variable biologic behavior. Mutations in the c-kit proto-oncogene are associated with the tumorigenesis of MCTs, resulting in growth factor-independent and constitutive phosphorylation of the KIT receptor tyrosine kinase (RTK). Toceranib (TOC) phosphate (Palladia®) is a KIT RTK inhibitor that has biological activity against MCTs. Despite these benefits, patients ultimately develop resistance to TOC. Therefore, there is a need to identify distinguishing clinical and molecular features of resistance in this population. Results The canine C2 mastocytoma cell line contains an activating mutation in c-kit. Three TOC-resistant C2 sublines (TR1, TR2, TR3) were established over seven months by growing cells in increasing concentrations of TOC. TOC inhibited KIT phosphorylation and cell proliferation in a dose-dependent manner in the treatment-naïve, parental C2 line (IC50 < 10 nM). In contrast, the three sublines were resistant to growth inhibition by TOC (IC50 > 1,000 nM) and phosphorylation of the KIT receptor was less inhibited compared to the TOC-sensitive C2 cells. Interestingly, sensitivity to three structurally distinct KIT RTK inhibitors was variable among the sublines, and all 3 sublines retained sensitivity to the cytotoxic agents vinblastine and lomustine. Sequencing of c-kit revealed secondary mutations in the juxtamembrane and tyrosine kinase domains of the resistant sublines. These included point mutations in TR1 (Q574R, M835T), TR2 (K724R), and TR3 (K580R, R584G, A620S). Additionally, chronic TOC exposure resulted in c-kit mRNA and KIT protein overexpression in the TOC-resistant sublines compared to the parental line. C2, TR1, TR2, and TR3 cells demonstrated minimal P-glycoprotein (P-gp) activity and no functional P-gp. Conclusions This study demonstrates the development of an in vitro model of acquired resistance to targeted therapy in canine MCTs harboring a c-kit-activating mutation. This model may be used to investigate the molecular basis of and strategies to overcome TOC resistance.
Collapse
Affiliation(s)
- Charles H C Halsey
- Program in Cell and Molecular Biology, Colorado State University, Fort Collins, CO, USA.
| | | | | | | | | | | | | | | |
Collapse
|
94
|
The Relevance of CD117-Immunocytochemistry Staining Patterns to Mutational Exon-11 in c-kit Detected by PCR from Fine-Needle Aspirated Canine Mast Cell Tumor Cells. Vet Med Int 2014; 2014:787498. [PMID: 24701365 PMCID: PMC3950358 DOI: 10.1155/2014/787498] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2013] [Accepted: 12/28/2013] [Indexed: 11/17/2022] Open
Abstract
Canine cutaneous mast cell tumors (MCT) are the lethal skin tumors. The biological behavior of the MCT cells is quite varied and unpredictable. Almost MCT dogs usually require a rapid diagnosis and therapy. However, MCT diagnosis and prognosis are still dependent on histopathology which is rather inconvenient, time-consuming, painful, and harmful for some cases. Indeed, MCT can be easily accessible using fine-needle aspiration (FNA). In this study, our biopsy specimens were classified as low- and high-grade MCT based on the novel 2-tier histopathologic grading system. We have demonstrated the usage of fine-needle aspirated MCT cells (FNA-MCT cells) from these specimens as a primary cell source to study the distribution of CD117-immunocytochemistry (CD117-ICC) staining patterns and the frequency of internal tandem duplication- (ITD-) mutant exon-11 of c-kit. The result has substantially shown that there were three staining patterns identified in the cells. Only paranuclear pattern was significantly increased in the cells from high-grade MCT. Altogether, the ITD-mutant exon-11 was also detectable only in these cells. Therefore, the result has supported our hypothesis that there was an increased opportunity to observe a higher CD117-ICC staining pattern and exon-11 mutation in high-grade MCT; even these two parameters may not precisely indicate a histopathological grade.
Collapse
|
95
|
Maes RK, Langohr IM, Wise AG, Smedley RC, Thaiwong T, Kiupel M. Beyond H&E: integration of nucleic acid-based analyses into diagnostic pathology. Vet Pathol 2013; 51:238-56. [PMID: 24129897 DOI: 10.1177/0300985813505878] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Veterinary pathology of infectious, particularly viral, and neoplastic diseases has advanced significantly with the advent of newer molecular methodologies that can detect nucleic acid of infectious agents within microscopic lesions, differentiate neoplastic from nonneoplastic cells, or determine the suitability of a targeted therapy by detecting specific mutations in certain cancers. Polymerase chain reaction-based amplification of DNA or RNA and in situ hybridization are currently the most commonly used methods for nucleic acid detection. In contrast, the main methodology used for protein detection within microscopic lesions is immunohistochemistry. Other methods that allow for analysis of nucleic acids within a particular cell type or individual cells, such as laser capture microdissection, are also available in some laboratories. This review gives an overview of the factors that influence the accurate analysis of nucleic acids in formalin-fixed tissues, as well as of different approaches to detect such targets.
Collapse
Affiliation(s)
- R K Maes
- College of Veterinary Medicine, Michigan State University, 4125 Beaumont Road, Lansing, MI 48910, USA. and
| | | | | | | | | | | |
Collapse
|
96
|
Ramos-Vara JA, Miller MA. When tissue antigens and antibodies get along: revisiting the technical aspects of immunohistochemistry--the red, brown, and blue technique. Vet Pathol 2013; 51:42-87. [PMID: 24129895 DOI: 10.1177/0300985813505879] [Citation(s) in RCA: 250] [Impact Index Per Article: 22.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Once focused mainly on the characterization of neoplasms, immunohistochemistry (IHC) today is used in the investigation of a broad range of disease processes with applications in diagnosis, prognostication, therapeutic decisions to tailor treatment to an individual patient, and investigations into the pathogenesis of disease. This review addresses the technical aspects of immunohistochemistry (and, to a lesser extent, immunocytochemistry) with attention to the antigen-antibody reaction, optimal fixation techniques, tissue processing considerations, antigen retrieval methods, detection systems, selection and use of an autostainer, standardization and validation of IHC tests, preparation of proper tissue and reagent controls, tissue microarrays and other high-throughput systems, quality assurance/quality control measures, interpretation of the IHC reaction, and reporting of results. It is now more important than ever, with these sophisticated applications, to standardize the entire IHC process from tissue collection through interpretation and reporting to minimize variability among laboratories and to facilitate quantification and interlaboratory comparison of IHC results.
Collapse
Affiliation(s)
- J A Ramos-Vara
- Animal Disease Diagnostic Laboratory and Department of Comparative Pathobiology, Purdue University, 406 South University, West Lafayette, IN 47907, USA.
| | | |
Collapse
|
97
|
Zhang A, Chi X, Luo G, Hei Z, Xia H, Luo C, Wang Y, Mao X, Xia Z. Mast cell stabilization alleviates acute lung injury after orthotopic autologous liver transplantation in rats by downregulating inflammation. PLoS One 2013; 8:e75262. [PMID: 24116032 PMCID: PMC3792971 DOI: 10.1371/journal.pone.0075262] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2013] [Accepted: 08/12/2013] [Indexed: 12/16/2022] Open
Abstract
Background Acute lung injury (ALI) is one of the most severe complications after orthotopic liver transplantation. Amplified inflammatory response after transplantation contributes to the process of ALI, but the mechanism underlying inflammation activation is not completely understood. We have demonstrated that mast cell stabilization attenuated inflammation and ALI in a rodent intestine ischemia/reperfusion model. We hypothesized that upregulation of inflammation triggered by mast cell activation may be involve in ALI after liver transplantation. Methods Adult male Sprague–Dawley rats received orthotopic autologous liver transplantation (OALT) and were executed 4, 8, 16, and 24 h after OALT. The rats were pretreated with the mast cell stabilizers cromolyn sodium or ketotifen 15 min before OALT and executed 8 h after OALT. Lung tissues and arterial blood were collected to evaluate lung injury. β-hexosaminidase and mast cell tryptase levels were assessed to determine the activation of mast cells. Tumor necrosis factor α (TNF-α), interleukin (IL)-1β and IL-6 in serum and lung tissue were analyzed by enzyme-linked immunosorbent assay. Nuclear factor-kappa B (NF-κB) p65 translocation was assessed by Western blot. Results The rats that underwent OALT exhibited severe pulmonary damage with a high wet-to-dry ratio, low partial pressure of oxygen, and low precursor surfactant protein C levels, which corresponded to the significant elevation of pro-inflammatory cytokines, β-hexosaminidase, and tryptase levels in serum and lung tissues. The severity of ALI progressed and maximized 8 h after OALT. Mast cell stabilization significantly inhibited the activation of mast cells, downregulated pro-inflammatory cytokine levels and translocation of NF-κB, and attenuated OALT-induced ALI. Conclusions Mast cell activation amplified inflammation and played an important role in the process of post-OALT related ALI.
Collapse
Affiliation(s)
- Ailan Zhang
- Department of Anesthesiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou City, People's Republic of China
| | - Xinjin Chi
- Department of Anesthesiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou City, People's Republic of China
| | - Gangjian Luo
- Department of Anesthesiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou City, People's Republic of China
| | - Ziqing Hei
- Department of Anesthesiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou City, People's Republic of China
- * E-mail:
| | - Hua Xia
- Department of Anesthesiology, the Affiliated Hospital of Luzhou Medical College, Luzhou City, People's Republic of China
| | - Chenfang Luo
- Department of Anesthesiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou City, People's Republic of China
| | - Yanling Wang
- Department of Anesthesiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou City, People's Republic of China
| | - Xiaowen Mao
- Department of Anesthesiology, Research Centre of Heart, Brain, Hormone and Healthy Aging, University of Hong Kong, Hong Kong SAR, People's Republic of China
| | - Zhengyuan Xia
- Department of Anesthesiology, Research Centre of Heart, Brain, Hormone and Healthy Aging, University of Hong Kong, Hong Kong SAR, People's Republic of China
| |
Collapse
|
98
|
Pabilonia KL, Podell BK, Powers BE. Pathology in practice. Mast cell tumor (MCT) of the oral mucosa with submandibular lymph node metastasis in a dog. J Am Vet Med Assoc 2013; 243:795-7. [PMID: 24004225 DOI: 10.2460/javma.243.6.795] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Affiliation(s)
- Kristy L Pabilonia
- Department of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.
| | | | | |
Collapse
|
99
|
Clarke L, Simon A, Ehrhart EJ, Mulick J, Charles B, Powers B, Duncan C. Histologic Characteristics and KIT Staining Patterns of Equine Cutaneous Mast Cell Tumors. Vet Pathol 2013; 51:560-2. [DOI: 10.1177/0300985813493931] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Mast cell tumors are uncommon in horses and typically have a benign clinical course, but there are occasional reports of more aggressive behavior. The objective of this study was to review histologic features and KIT expression patterns of 72 previously diagnosed equine cutaneous mast cell tumors to determine if either is associated with clinical outcomes. Biopsy specimens were reviewed using histologic criteria derived from grading schemes, and KIT antibody expression patterns used in canine tumors and surveys were sent to referring veterinarians for follow-up clinical data. Arabians were overrepresented relative to the reference population. Most tumors were well differentiated with low mitotic rates (96%), and aberrant KIT staining patterns, as described in dogs, were uncommonly identified (12%). Associated clinical disease was uncommon and no tumors exhibited malignant behavior. Overall, KIT staining pattern and histologic features were not associated with poor clinical outcome or abnormal tumor behavior.
Collapse
Affiliation(s)
- L. Clarke
- Department of Pathology, University of Georgia, Athens, GA, USA
| | - A. Simon
- Colorado State University Veterinary Diagnostic Laboratory, Fort Collins, CO, USA
| | - E. J. Ehrhart
- Colorado State University Veterinary Diagnostic Laboratory, Fort Collins, CO, USA
| | - J. Mulick
- Colorado State University Veterinary Diagnostic Laboratory, Fort Collins, CO, USA
| | - B. Charles
- Colorado State University Veterinary Diagnostic Laboratory, Fort Collins, CO, USA
| | - B. Powers
- Colorado State University Veterinary Diagnostic Laboratory, Fort Collins, CO, USA
| | - C. Duncan
- Colorado State University Veterinary Diagnostic Laboratory, Fort Collins, CO, USA
| |
Collapse
|
100
|
Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: A retrospective cohort study. Vet J 2013; 196:492-8. [DOI: 10.1016/j.tvjl.2012.11.018] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2012] [Revised: 11/19/2012] [Accepted: 11/25/2012] [Indexed: 11/23/2022]
|